Abstract
The recent progress in the success of therapeutic effects on osteogenic sarcoma has been extraordinary and greatly enhanced by the contribution of adjuvant chemotherapy [1]. The number of treatment courses in adjuvant chemotherapy that will be adequate to eradicate all tumor cells has become a matter of concern. The principles involved in this matter and a tentative conclusion are presented by an analysis of the therapeutic results of 48 patients with osteogenic sarcoma.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, Marcove RC, Lane JM, Mehta B, Urban C (1982) Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49: 1221–1230
Skipper H, Schabel FM Jr, Wilcox WS (1964) Experimental evaluation of potential anticancer agents. XIV. Further study of certain basic concepts underlying chemotherapy of leukemia. Cancer Chemother Rep 45: 5–28
Rosen G (1985) Preoperative (neoadjuvant) chemotherapy for osteogenic sarcoma: A ten-year experience. Orthopedics 8: 659–664
Frei E, Jaffe N, Gero M, Skipper H, Watts H (1978) Adjuvant chemotherapy of osteogenic sarcoma: Progress and perspectives. J Natl Cancer Inst 60: 3–10
Cortes EP, Holland JF, Wang JJ, Glidewell 0 (1975) Adriamycin (NSC-123127) in 87 patients with osteosarcoma. Cancer Chemother Rep 6 (Part 3): 305–313
Ochs JJ, Freeman AI, Douglass HO Jr, Higby DS, Mindell ER, Sinks LF (1978) Cis-dichlorodiammine-platinum ( II) in advanced osteogenic sarcoma. Cancer Treat Rep 62: 239–245
Vogl S, Ohnuma T, Perloff M, Holland J (1976) Combination chemotherapy with Adriamycin and cis-diamminedichloroplatinum in patients with neoplastic disease. Cancer 38: 21–26
Rosen G, Marcove RC, Caparros B, Nirenberg A, Kosloff C, Huvos A (1976) Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery. Cancer 43: 2163–2177
Colvin M, Brundrett RB, Kan MNN, Jardine I, Fenselau C (1976) Alkylating properties of phosphoramide mustard. Cancer Res 36: 1121–1126
Shimoyama M, Niitani H, Kimura K (1975) Chemotherapeutic effect of cyclophosphamide and its related active compounds. 3. A design of optimal therapeutic schedules of these compounds (in Japanese). Jpn J Cancer Chemother 2: 889–901
Bagley CM Jr, Bostick FW, DeVita VT Jr (1973) Clinical pharmacology of cyclophosphamide. Cancer Res 33: 226–233
Frei E III, Freireich EJ (1965) Progress and perspectives in the chemotherapy of acute leukemia. Adv Chemother 2: 269–298
Goldie JH, Coldman AJ (1979) A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63: 1727–1733
Goldie JH, Coldman AJ, Gudauskas GA (1982) Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 66: 439–449
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer Japan
About this paper
Cite this paper
Fujimoto, S. (1992). Principles of Adjuvant Chemotherapy for Bone and Soft Tissue Tumors. In: Uchida, A., Ono, K. (eds) Recent Advances in Musculoskeletal Oncology. Springer, Tokyo. https://doi.org/10.1007/978-4-431-68364-3_7
Download citation
DOI: https://doi.org/10.1007/978-4-431-68364-3_7
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-68366-7
Online ISBN: 978-4-431-68364-3
eBook Packages: Springer Book Archive